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IntroductIon
The past four decades have witnessed a rapidly increasing inci-
dence of oesophageal adenocarcinoma (OAC) in many Western 
countries, e.g., in North America, Europe, and Australia [1–5]. 
OAC is usually diagnosed at advanced stages and thus carries a 
poor prognosis with an overall 5-year survival lower than 20% in 
most developed countries [2, 5–7]. Detection at an early tumour 
stage would substantially reduce the mortality [2, 6]. Endoscopy 
provides an opportunity for early detection of OAC or its pre-
malignant condition Barrett’s oesophagus with dysplasia [8, 9]. 
However, universal endoscopic screening is not feasible given the 
low incidence in the general population, considerable costs, and 
complications and inconveniences associated with endoscopy [9, 
10]. Instead, it would be preferable to target a limited group of 
individuals with high absolute risk who may benefit from endo-
scopic screening.
Risk prediction modelling based on information on risk factors 
has shown promising usefulness in selecting individuals at high 
absolute risk of cardiovascular disease and breast, colorectal, and 
lung cancers [11–14]. Yet, only two prediction models have been 
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developed for OAC, one in an Australian population and the other 
in a Swedish population [15–17]. The models provided by these 
studies were promising, but remain to be validated in external 
populations, and because they were based on case–control stud-
ies, they also require validation in terms of risk calibration in a 
prospective design.
Therefore, we aimed to evaluate a prediction model for identify-
ing individuals at high absolute risk of OAC based on a prospective 
population-based cohort study in Norway.
MEtHodS
Study design and data source
The Nord-Trøndelag Health Study (HUNT) is a prospective cohort 
study including the majority of adult residents in Nord-Trøndelag 
County in Norway. HUNT consists of a series of population-based 
health surveys initiated in the mid-1980s. These surveys include 
data from questionnaires and clinical measurements on basic 
demographics, health-related behaviours, symptoms, diseases, 
and body composition of the participants [18]. The present study 
was based on data from the second survey (HUNT2) conducted 
in 1995–1997, which was the first survey that included the assess-
ment of gastro-oesophageal reflux symptoms. Among 93,898 
adult residents aged over 20 years in the county, 64,975 (69%) 
participated by answering the questionnaires and taking part in 
the clinical measurements. For the purpose of the present study, 
2399 participants with any prior cancer diagnosis were excluded, 
and thus the final study cohort consisted of 62,576 participants. 
All participants were followed up from the date of taking part 
in the HUNT2 survey until the date of diagnosis of OAC, death, 
emigration, or the end of the study (31 December 2015), which-
ever occurred first. Information on incident OAC cases, death, 
and emigration was retrieved through linkage to the nationwide 
Cancer Registry of Norway, and Statistics Norway, respectively. 
The linkages of individuals’ data between registries were enabled 
by the unique personal identity number, which was available for 
each study participant.
Predictors and model development
The pre-defined predictors evaluated in the model were five well-
established risk factors for OAC, i.e., age, sex, gastro-oesophageal 
reflux symptoms, obesity, and tobacco smoking status [2, 5]. 
Data on age and sex were collected at the time of participation in 
HUNT. Gastro-oesophageal reflux symptoms were assessed using 
questionnaires, where participants were asked: ‘To what degree 
have you had heartburn or acid regurgitation during the previous 
12 months?’ and replied with one of three response alternatives: 
‘no complaints’, ‘minor complaints’, or ‘severe complaints’ [19, 20]. 
Use of this questionnaire has been well validated as representing 
gastro-oesophageal reflux disease in a previous validation study 
in HUNT. The severe complaints answer responded well to reflux 
disease with a high specificity of 99.5%. Among the participants 
who reported minor symptoms in the validation study, 15% had 
daily symptoms or had used anti-reflux medication on a daily 
basis, 10% had at least weekly symptoms, and 75% had symptoms 
less frequently than weekly [19]. Weight and height were measured 
under standardised conditions by trained personnel at screening 
stations, providing an objective assessment of body mass index 
(BMI), which was calculated by dividing weight in kilograms by 
the squared height in metres (kg/m2). Obesity was defined accord-
ing to the definition stated by the World Health Organisation as a 
BMI of 30 or above. Participants were asked using the question-
naires about their smoking status and were classified as current 
daily smokers, previous daily smokers, or never daily smokers [21].
Competing-risk regression was used to assess associations 
between the candidate predictors and the risk of OAC and to esti-
mate the absolute risk of OAC in individual participants. The com-
peting-risk regression is based on the method of Fine and Gray 
and estimates the sub-hazard ratio (SHR) for OAC in the presence 
of competing risk from death [22–24]. The absolute risks of OAC 
within 10 years and within 15 years from participation were pro-
jected for individuals with different combinations of risk factors by 
the cumulative incidence functions derived from the competing-risk 
regression. The cumulative incidence function estimates the prob-
ability of developing OAC in the presence of competing risks from 
death within a specific period of time. We dichotomised sex, reflux 
symptoms (yes, either minor or severe, or no), obesity (BMI < 30 
or ≥ 30), and daily tobacco smoking (ever or never) and grouped 
age into four categories (<50, 50–59, 60–69, or ≥70 years). Interac-
tions were not considered due to the limited number of OAC cases.
Analysis of performance and validation
We assessed the model performance in terms of discriminative 
accuracy using two measurements, i.e., the area under the receiver 
operating characteristic curve (AUC) and Somers’ D statistic. The 
AUC measures the model’s ability to discriminate participants 
developing OAC from those who do not, after a specific time 
period of follow-up based on predicted risk at baseline, whereas 
Somers’ D estimates the association between the predicted risks 
and observed outcomes [25]. To overcome the problem of over-
fitting when the model performance is evaluated with the same 
dataset as used in the model building, the statistics were re-cal-
culated using the 10-fold cross-validation strategy. We randomly 
divided all participants into 10 approximately equal groups, and 
predicted the risks for the participants in each group from a model 
excluding this group. The unbiased AUC and Somers’ D statis-
tics were calculated with the predicted risks based on the 10-fold 
cross-validation. The calibration was examined by plotting the 
agreement between the cumulative predicted risks and cumula-
tive observed proportions of OAC cases across tenths of predicted 
risk. Those with predicted risks below the 60th percentile were 
combined into one group because no OAC cases occurred. Due to 
the limited number of OAC patients in each risk category, statisti-
cal calibration test or calibration slope were not calculated [26].
Lorenz curve
The Lorenz curve is an established graphical representation of the 
distribution of income or of wealth in econometrics, which has 
also been proposed for evaluating the ‘concentration’ of disease 
risks in the population [17, 27]. In this study, we used the Lorenz 
curve to assess the concentration of OAC patients occurring in 
individuals at high risk based on the prediction model. We ranked 
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all participants based on their predicted risks from the model. For 
each level of predicted risk, we calculated the cumulative propor-
tion of participants with this level of risk or below to the entire 
cohort and, correspondingly, the cumulative proportion of OAC 
patients occurring among these participants within 10 years or 
15 years of follow-up. We plotted the cumulative proportion of 
the population (x-axis) against the cumulative proportion of cases 
in each risk level (y-axis). The greater the degree to which cases 
are concentrated in a small number of high-risk individuals, the 
greater the deflection of the Lorenz curve downward from the line 
of equality, and the higher yield of screening programme targeting 
high-risk subsets of the population.
External validation of the Swedish prediction model
Using data from HUNT2, we externally assessed a previous 
prediction model derived from a nationwide population-based 
case–control study in Sweden which included 189 histologically 
confirmed incident cases of OAC and 820 age- and sex-matched 
control subjects [16]. We modified the Swedish model so that 
the included predictors, i.e. age, sex, reflux symptoms, BMI, and 
tobacco smoking, were in the same categories as in the current 
study (Supplementary Table  1). Methods of model develop-
ment have been described in detail previously [16]. This Swed-
ish model predicts the 5-year risk of OAC, which was used as a 
proxy for long-term risk hereby and validated against the occur-
rence of OAC in 15 years among participants of the HUNT2 
cohort. The performance of this Swedish model was assessed in 
terms of both discriminative accuracy and risk calibration.
All statistical analyses were performed using the statistical soft-
ware SAS version 9.4 (SAS Institute, Cary, NC). All P values are 
two-sided, and a P value of less than 0.05 was considered statisti-
cally significant.
Ethical approval
The study was approved by the Regional Committee for Medical and 
Health Research Ethics in Norway (reference number 2016/2040/
REK sør-øst A). All participants in HUNT gave written informed 
consent when participating stating that their data could be used in 
future medical research, including linkage to other registries.
rESultS
Study participants
The final study cohort of 62,576 participants included 29,509 
(47.2%) males and 33,067 (52.8%) females, with a mean age at 
baseline of 49.6 years. Some baseline characteristics of the study 
participants are shown in Table 1. Among all participants, 16.4% 
were obese (BMI ≥ 30), 28.2% had reflux symptoms, and 55.2% 
were daily tobacco smokers. During a total of 1,085,137 person-
years of follow-up, 29 incident cases of OAC occurred.
Competing-risk regression
The competing-risk regressions showed that male sex, older age, 
presence of gastro-oesophageal reflux symptoms, obesity, and daily 
tobacco smoking predicted higher risk of OAC (Table 2). The pre-
dicted absolute risk of OAC varied greatly according to individuals’ 
risk factor profiles; the 15-year risk ranged from 3.6/100,000 to 
292.5/100,000 (Table 3). The highest 15-year absolute risk of OAC 
(292.5/100,000) was predicted for males aged 60–69 years who 
had reflux symptoms, were obese, and smoked daily. In this group, 
342 individuals are needed to be surveyed to detect one OAC case 
within 15 years. An interactive web tool to estimate an individual’s 
absolute risk of OAC in 15 years based on this model, the Oesoph-
ageal Adenocarcinoma Risk Assessment Tool, can be accessed at 
https://sites.google.com/view/oacrisk. A screen shot of this online 
risk assessment tool is shown in Supplementary Figure 1.
Model performance
Table 4 shows the discriminative accuracy of the model with and 
without 10-fold cross-validation. The AUC for the risk of OAC 
within 10 years was 0.81 (95% confidence interval (CI) 0.70–0.91) 
and for the risk within 15 years was 0.88 (95% CI 0.83–0.93). The 
AUC statistics declined after cross-validation for the 10-year risk 
(AUC 0.71, 95% CI 0.57–0.85) and slightly also for the 15-year 
Table 1 Basic characteristics of study participants
Characteristic at 
baseline
Number of participants 
(%)
Number of person-
years
total 62,576 (100) 1,085,137
Sex
 Male 29,509 (47.2) 502,955
 Female 33,067 (52.8) 582,182
Age, years
 <50 33,718 (53.9) 647,632
 50–59 10,605 (17.0) 195,264
 60–69 8473 (13.5) 137,076
 ≥70 9780 (15.6) 105,164
 Mean ± standard  
deviation
49.6±17.1
Body mass index
 <30 51,855 (82.9) 908,454
 ≥30 10,236 (16.4) 171,537
 Missing 485 (0.8) 5146
 Mean ± standard  
deviation
26.3±4.1
Reflux symptoms
 No 38,931 (62.2) 689,832
 Minor 14,637 (23.4) 256,689
 Severe 3024 (4.8) 52,477
 Missing 5984 (9.6) 86,139
Daily tobacco smoking
 Never 26,643 (42.6) 469,403
 Former 16,675 (26.6) 281,828
 current 17,911 (28.6) 313,882
 Missing 1347 (2.2) 20,024
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risk (AUC 0.84, 95% CI 0.76–0.91). The calibration plot showed 
good agreement between observed and predicted cumulative 
risks of OAC within 15 years (Fig. 1).
Lorenz curve
Figure 2 shows the Lorenz curve constructed with individuals’ esti-
mated risks of OAC within 10 years and within 15 years based on 
the prediction model. The analysis indicated substantial concentra-
tion of OAC cases in individuals at high risk as estimated by the 
prediction model. Among all OAC cases occurring within 15 years, 
33% would have occurred in the 5% of the population of the highest 
risks, and 61% in the top 10% of the population. The thresholds of 
the 15-year risk to include the top 5, 10, and 20% of the population 
at the highest risks and the corresponding numbers of individuals 
to be surveyed to detect one OAC case are also illustrated in Fig. 2.
External validation of the Swedish prediction model
Applying the Swedish risk prediction model to the HUNT2 popu-
lation gave an AUC of 0.89 (95% CI 0.84–0.94) for the 15-year 
risk of OAC, and showed good calibration between observed 
and predicted cumulative risks (Supplementary Figure 2). How-
ever, most data points in the calibration plot are above the line of 
perfect agreement (Supplementary Figure 2), indicating that the 
predicted cumulative risks are generally lower than the observed 
cumulative risks in individuals with relatively lower risks.
dIScuSSIon
This study provides a model for predicting individuals’ absolute 
risk of OAC based on a panel of established risk factors derived 
from a prospective cohort study. The model had good discrimi-
native accuracy, particularly for predicting 15-year risk of OAC. 
The agreement between the observed and predicted risks showed 
good calibration. The Lorenz curve suggested a clear concentra-
tion of OAC cases in high-risk individuals based on the developed 
prediction model, and thus indicated a high-yield target group for 
potential endoscopy screening.
To our knowledge, this is the first risk prediction model of OAC 
developed from a prospective study. The cohort design counter-
acted information misclassification as compared with standard 
case–control studies and enabled evaluation of the model perfor-
mance in terms of risk calibration. Other strengths of this study 
include the population-based design, objectively assessed anthro-
pometric measures, well-validated data on reflux symptoms [19, 
20], and complete and long follow-up. A weakness is the small 
number of OAC cases occurring during follow-up, which is due 
to the limited number of person-years of follow-up in this low-
incidence population of OAC. This reduced the precision of the 
predicted risk estimates and the ability to categorise the predictors 
into several groups. In addition, lack of information on use of anti-
reflux medications in this study might have led to reduced model 
precision. A larger sample size with longer follow-up and more 
detailed information on risk factors may enable greater granularity 
in terms of further classifying reflux symptoms based on severity 
or frequency, more precise categorisation of BMI, and quantita-
tive assessment of tobacco smoking and, consequently, improve 
the performance of the model in identifying individuals with 
extremely high risk of OAC. Although the model performance was 
assessed with the cross-validation strategy, there remains a risk of 
model over-fitting because the model performance was assessed 
with data on individuals in the same cohort as used to build the 
model. Therefore, an external validation of the prediction model 
in an independent population would be ideal. Moreover, as the 
Lorenz curve is dependent on the distribution of risk factors in the 
population and may differ across populations, the curve shown in 
this study may not be generalisable to other populations.
To the best of our knowledge, there are only two previous pre-
diction models for estimating the absolute risk of OAC, and these 
were based on data from case–control studies in Australia and 
Sweden [15, 16]. The predictors in these models included the five 
predictors used in the present study together with other factors. 
These earlier models also showed good discriminative accuracy 
with the AUC statistics ranging from 0.75 to 0.85 after cross- 
validation, depending on which predictors were included. The two 
previous case–control studies were unable to assess the calibra-
tion of the predicted and observed risks. External validation of the 
previous Swedish model using data from the HUNT cohort 
provided an AUC even higher than that for the original logistic 
models, which could be explained by contribution from the two 
additional important predictors, i.e., age and sex, in the final 
model. When applying the Swedish model to the HUNT popula-
tion, the calibration plot indicated over-fitting of the model, i.e., 
Table 2 Associations between risk factors and oesophageal 
adenocarcinoma from competing-risk regression, expressed 
as sub-hazard ratios (SHR) with 95% confidence interval (CI) 
(N = 62,576)
Variables at 
baseline
Number of 
cases
Crude SHR  
(95% CI)
Adjusted SHR  
(95% CI)a
Sex
Female 9 1.0 (Reference) 1.0 (Reference)
Male 20 2.5 (1.1–5.5) 1.9 (0.8–4.2)
Age, years
<50 8 1.0 (Reference) 1.0 (Reference)
50–59 6 2.4 (0.8–6.9) 2.1 (0.7–6.0)
60–69 8 4.0 (1.5–10.6) 3.2 (1.1–8.9)
≥70 7 3.0 (1.1–8.3) 3.1 (1.1–8.9)
Body mass index
<30 21 1.0 (Reference) 1.0 (Reference)
≥30 8 1.9 (0.9–4.4) 1.8 (0.7–4.1)
Reflux symptoms
No 9 1.0 (Reference) 1.0 (Reference)
Yes 18 4.4 (2.0–9.8) 3.7 (1.6–8.4)
Daily tobacco smoking
Never 6 1.0 (Reference) 1.0 (Reference)
Ever 23 3.0 (1.2–7.3) 2.1 (0.8–5.5)
aParticipants with missing values of predictors (n = 7210) were excluded from 
the multivariate competing-risk regression
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underestimated risks in low-risk individuals and overestimated 
risks in high-risk individuals. However, the calibration plots in this 
study should be interpreted with caution considering the small 
number of observed cancer patients in each risk category. Based 
on information on the five major risk factors for OAC only, the 
prediction model provided in this study is the simplest, and yet the 
discriminative ability was promising with a high AUC (0.84) for 
15-year risk after cross-validation. Compared with risk prediction 
models for other cancers, the models used for OAC, including the 
present one, seem to have higher discriminative accuracy as meas-
ured by the AUC statistics. The Lorenz curve in the present study 
indicated higher concentration compared with the curve based on 
the previous Swedish study in which OAC cases and control sub-
jects were matched by age and sex, confirming the importance of 
considering age and sex for targeted prevention and screening.
Despite decades of efforts to develop the treatment, the prog-
nosis of OAC has improved to only a limited extent [5–7]. How-
ever, unselective endoscopic screening or surveillance to detect 
early and thus curable OAC is not justified given the low absolute 
risk of OAC even in reflux patients (~20/100,000 per year) [10]. In 
this study, the Lorenz curve indicated that targeting the top 10% 
individuals based on individual risk assessment would have iden-
tified 61% of all OAC cases occurring within 15 years and prob-
ably more cases with even longer follow-up, while in as many as 
28% of the total population who had reflux, only 62% of all OAC 
cases occurred. Therefore, an individual risk assessment based on 
prediction modelling of some key factors could help better tailor 
screening programmes compared with relying on reflux symptoms 
only (surveying 10% versus 28% of the population to have the 
same yield). In contrast, none of the OAC cases in this study were 
from the bottom 60% of the population with the lowest estimated 
risks. These individuals generally corresponded to non-smoking 
men and women younger than 50 years and without reflux symp-
toms, and thus should not be considered for screening. The Clini-
cal Guidelines Committee of the American College of Physicians 
recommends endoscopic investigation in men aged over 50 years 
with long-term reflux symptoms and additional risk factors, but 
not in the general population [28]. The conceptual basis for this 
recommendation is similar to an individual risk assessment based 
on multiple risk factors in seeking for a more precise high-risk 
group, but a risk prediction model would provide a more objective 
tool to assist clinical decision making and public health recom-
mendations. Particularly, despite the male predominance in the 
Table 3 Estimated 15-year cumulative risk of oesophageal adenocarcinoma with selected profiles of risk factors
Profile Sex Age (years) Reflux symptoms Obesity Daily tobacco 
smoking
15-Year risk per 
100,000
Number to survey to detect 
one case within 15 years
1 Female <50 No No Never 3.6 27,908
2 Female 50–59 Yes No Ever 58.8 1701
3 Female 50–59 Yes Yes Ever 102.9 915
4 Female 60–69 Yes Yes Ever 157.4 635
5 Male <50 No No Never 6.7 15,008
6 Male <50 Yes No Never 24.6 4061
7 Male 50–59 Yes No Never 50.9 1962
8 Male <50 No Yes Ever 25.0 3994
9 Male ≥70 Yes No Ever 162.9 614
10 Male 60–69 Yes Yes Ever 292.5 342
Table 4 Discriminative ability of the model for predicting 10-year 
and 15-year risks of oesophageal adenocarcinoma, expressed as 
area under the receiver operating characteristic curve (AUC) with 
95% confidence interval (CI) and Somers’ D
10-Year risk 15-Year risk
AUC  
(95% CI)
Somers’ 
D
AUC  
(95% CI)
Somers’ 
D
Derivation  
cohort
0.81 
(0.70–0.91)
0.61 0.88 
(0.83–0.93)
0.76
10-Fold cross-
validation
0.71 
(0.57–0.85)
0.41 0.84 
(0.76–0.91)
0.67
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Fig. 1 calibration of observed cumulative proportion of oesophageal 
adenocarcinoma patients and cumulative predicted risk in 15 years
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incidence of OAC, female patients still account for a substantial 
proportion (1/7 in European populations) of all OAC cases [2]. 
The current guidelines do not recommend screening in women, 
regardless of reflux symptoms, considering the low average risk 
in women, while a risk prediction model may provide more indi-
vidualised risk assessment and identify women with considerably 
high risk who may still benefit from screening. Because informa-
tion on the risk factors included in the present model can be easily 
obtained, the model can be straightforwardly applied in clinical 
practice, particularly with the help of a user-friendly online risk 
assessment tool, and is readily amenable for external validation. 
Further validation and evaluation of the risk prediction model is 
recommended particularly in populations with particularly high 
incidence of OAC, e.g., in the United Kingdom [29].
Thresholds of the predicted risk are necessary for clinical and 
public health practices, but these need to be carefully determined 
by taking into account the incidence of OAC in the population, 
perspectives of the healthcare providers and practitioners, and 
potential benefits and harms for the individuals. However, choos-
ing a risk threshold is beyond the scope of this study.
In summary, this population-based cohort study in Norway pro-
vides a model for predicting individuals’ risk of developing OAC by 
combining information on five readily identifiable risk factors. The 
model had good performance in terms of discriminative ability and 
calibration, but further external validation in larger populations is 
needed, preferably in countries with high incidence of OAC. Indi-
vidual risk assessment based on known risk factors for OAC has 
the potential of identifying individuals at high risk of OAC who 
may benefit from tailored screening and surveillance for detection 
of dysplastic Barrett’s oesophagus or early and curable OAC.
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Study Highlights
wHAT IS CURRENT kNOwLEDgE
✓✓ the incidence of oesophageal adenocarcinoma has been 
increasing rapidly in many Western populations.
✓✓ oesophageal adenocarcinoma is usually diagnosed at advanced 
stages with poor prognosis, stressing the need for early detection.
✓✓ unselected endoscopic screening is not feasible given the 
low absolute risk in the general population.
✓✓ risk prediction is a promising approach but has rarely been 
developed for oesophageal adenocarcinoma.
wHAT IS NEw HERE
✓✓We developed a prediction model for individuals’ absolute 
risk of oesophageal adenocarcinoma using data from a 
population-based cohort study.
✓✓ the model was based on information on a limited panel of 
established and readily identifiable risk factors.
✓✓ the prediction model had good discriminative accuracy and 
risk calibration.
✓✓ the prediction model could identify a limited group of high-risk 
individuals who may be considered for endoscopic screening.
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